MS Ventures backs Inthera Bioscience’s €3.4m round

Dutch VC Aglaia BioMedical Ventures, Danish investor Novo Seeds and startup agency EVA Basel also participated in the round.

Inthera plans to start clinical trials following the round of funding.

Aglaia invested via its Aglaia Oncology Fund II, which is solely focused on companies that develop treatments for cancer. It marks the second investment of the vehicle after last month's investment in Netherlands-based InteRNA Technologies. The fund has raised €50m so far, targeting a size between €60-80m at final close.

Company
Founded in 2013 and based in Zurich, Inthera focuses on the development of targeted small-molecule therapies for solid tumours. The company employs a proprietary technology platform to design protein-protein interaction inhibitors.

People
Ulrich Kessler is the CEO and co-founder of Inthera. Mark Krul is a partner at Aglaia. Jasper Bos is a senior investment director at MS Ventures. Nanna Lüneborg is an investment director at Novo Seeds. 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Venture
• Switzerland